Drugmaker Biogen is pulling the plug on its controversial Alzheimer's drug Aduhelm, following disappointing sales. It had been expected to be a blockbuster product. A drugmaker is pulling the plug on ...

The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works. By Rebecca Robbins The drug maker Biogen said on ...

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that ...